Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

Confo Therapeutics announces selection of first product candidate and initiation of pre-clinical development

News
- 15/10/2020
Ghent, Belgium: 15 October 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications.…
Read more

Nexstim continues to report promising results in quickly growing number of patients completing SmartFocus® rTMS treatment of Major Depressive Disorder

News
- 05/10/2020
Helsinki, Finland: 5 October 2020 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) reports very promising clinical outcomes of the 108 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD).…
Read more

Team
Dr Jos B. Peeters
Chairman of the Executive Committee - Responsible for venture capital, finance and IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.